Evidence map›Paper›PMID 38850571›Full record

ReviewAutoimmunity2024

Animal models of immune-mediated demyelinating polyneuropathies.

Eroboghene E Ubogu

Abstract readReview
In one paragraph

Review in Autoimmunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Eroboghene E UboguNeuromuscular Immunopathology Research Laboratory, Division of Neuromuscular Disease, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-8307-9994

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
Validation of Fibroblast-Derived PI16 as a Novel Target for pain TreatmentR01NS116704 · NINDS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEPHERD, ANDREW JOHN · 2020 to 2024
$3.6M
Vascular biology of the human blood-nerve barrierR01NS075212 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UBOGU, EROBOGHENE EKAMERENO · 2012 to 2016
$1.6M
Fibronectin peptide antagonism for chronic inflammatory neuropathiesR21NS073702 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UBOGU, EROBOGHENE EKAMERENO · 2011 to 2012
$430k
Alpha M Beta 2 integrin blockade for acute inflammatory neuropathiesR21NS078226 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UBOGU, EROBOGHENE EKAMERENO · 2012 to 2013
$424k
CD11d antagonism for chronic inflammatory neuropathiesR21NS109644 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UBOGU, EROBOGHENE EKAMERENO · 2019 to 2019
$408k
Alpha-1 catenin regulation of the mammalian blood-nerve barrierR21NS113033 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI UBOGU, EROBOGHENE EKAMERENO · 2020 to 2020
$408k
NIAID NIH HHS P30 AI027767NINDS NIH HHS R01 NS075212NINDS NIH HHS R01 NS116704NINDS NIH HHS R21 NS073702NINDS NIH HHS R21 NS078226NINDS NIH HHS R21 NS109644NINDS NIH HHS R21 NS113033
6 · The paper itself

Abstract

Immune-mediated demyelinating polyneuropathies (IMDPs) are rare disorders in which dysregulated adaptive immune responses cause peripheral nerve demyelinating inflammation and axonal injury in susceptible individuals. Despite significant advances in understanding IMDP pathogenesis guided by patient data and representative mammalian models, specific therapies are lacking. Significant knowledge gaps in IMDP pathogenesis still exist, e.g. precise antigen(s) and mechanisms that initially trigger immune system activation and identification of large population disease susceptibility factors. The initial directional cues for antigen-specific effector or autoreactive leukocyte trafficking into peripheral nerves are also unknown. An overview of current animal models, with emphasis on the experimental autoimmune neuritis and spontaneous autoimmune peripheral polyneuropathy models, is provided. Insights on the initial directional cues for peripheral nerve tissue specific autoimmunity using a novel Major Histocompatibility Complex class II conditional knockout mouse strain are also discussed, suggesting an essential research tool to study cell- and time-dependent adaptive immunity in autoimmune diseases.

Indexed as

Disease Models, AnimalAdaptive ImmunityAnimalsAutoimmunityHistocompatibility Antigens Class IIHumansMiceMice, KnockoutNeuritis, Autoimmune, ExperimentalObservational Studies, Veterinary as TopicPolyneuropathiesHistocompatibility Antigens Class IIAcute inflammatory demyelinating polyradiculoneuropathyanimal modelsblood-nerve barrierchronic inflammatory demyelinating polyradiculoneuropathydemyelinating neuritisexperimental autoimmune neuritismajor histocompatibility complexmicepathogenesisspontaneous autoimmune peripheral polyneuropathy

Identifiers

PMID38850571
PMCPMC11215812

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.